Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir

Table 3

Infant adverse events at birth associated with maternal lopinavir/ritonavir versus nelfinavir, in combination with zidovudine and lamivudine.

Laboratory test	Lopinavir/ritonavir	Nelfinavir	Odds ratio (95% CI); value
Hgb	2/34 (6%)	6/29 (21%)	6.3 (1.01–39.8)
ANC	2/22 (9%)	7/25 (28%)	N/A
AST	4/34 (12%)	7/25 (28%)	3.5 (0.73–16.7)
Highest grade AE, all tests	10/35 (29%)	17/29 (59%)	4.9 (1.6–15.4)

Hgb, hemoglobin; ANC, absolute neutrophil count; AST, aspartate aminotransferase.
Multivariate analysis using logistic regression was used to model grade ≥1 AE (yes/no) as a function of maternal antiretroviral treatment. Groups restricted to infants born to mothers treated with zidovudine/lamivudine in combination with either lopinavir/ritonavir or nelfinavir.
There were no adverse events for bilirubin, 1 adverse event for alanine aminotransferase in the lopinavir/ritonavir group, and 3 adverse events for platelet count in the nelfinavir group, not shown separately but included in the maximum adverse events.
Number of infants with adverse event/number of infants exposed (%).
Fisher’s exact test reported.